Loading…
Employees: 59
Size Evonile Pharma (EVONILE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $466M, the 870th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,758 on 6 Nov 2026.
Growth Revenue fell 5.2% over the last twelve months (peer median -3.4%); the operating margin is 12.2% (peer median -0.9%).
Valuation It trades at 14.5× enterprise value to sales against a peer median of 4.4× (2nd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +48 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.6 points below its cost of capital (9.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹3.36B | ₹3.54B | ₹3.56B | ₹3.35B | ₹3.79B |
| Revenue growth | — | -1% | +6% | -12% | — |
| Gross profit | ₹977M | ₹1.33B | ₹1.32B | ₹1.09B | ₹1.22B |
| EBITDA | ₹461M | ₹989M | ₹981M | ₹687M | ₹737M |
| Net income | -₹39.9M | ₹932M | ₹1.01B | ₹852M | ₹1.03B |
| Free cash flow | n/a | ₹844M | n/a | ₹1.48B | ₹644M |
| Capital expenditure | n/a | ₹3.40M | ₹0 | ₹0 | ₹3.10M |
| Total debt | ₹7.96B | ₹32.1M | ₹50.6M | ₹69.7M | ₹215M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EVONILE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| Revenue growth (TTM) | -5.2% | -3.4% | 10th lowest of 21 |
| Operating margin | 12.2% | -0.9% | 5th highest of 21 |
| EV / Sales | 14.5× | 4.4× | 2nd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 46.5% | 6.4% | most demanding of 9 |
| Growth delivered (Del g) | -1.5% | +0.9% | 2nd lowest of 9 |
| Hurdle (Req g minus delivered) | +48.0 pp | +4.8 pp | most demanding of 9 |
| ROIC minus cost of capital | -6.6 pp | -2.5 pp | 8th lowest of 18 |
| Net debt / EBITDA | 10.7× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 0.2× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | 4.4× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | 10.5× | n/a | n/a |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | 6.0× | n/a | n/a |